BioAffinity Current Deferred Revenue vs Total Liab Analysis
| BIAF Stock | USD 1.22 0.02 1.61% |
BioAffinity Technologies, financial indicator trend analysis is way more than just evaluating bioAffinity Technologies, prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether bioAffinity Technologies, is a good investment. Please check the relationship between BioAffinity Technologies, Current Deferred Revenue and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in bioAffinity Technologies,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.
Current Deferred Revenue vs Total Liab
Current Deferred Revenue vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of bioAffinity Technologies, Current Deferred Revenue account and Total Liab. At this time, the significance of the direction appears to have no relationship.
The correlation between BioAffinity Technologies,'s Current Deferred Revenue and Total Liab is 0.04. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Total Liab in the same time period over historical financial statements of bioAffinity Technologies,, assuming nothing else is changed. The correlation between historical values of BioAffinity Technologies,'s Current Deferred Revenue and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of bioAffinity Technologies, are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Current Deferred Revenue i.e., BioAffinity Technologies,'s Current Deferred Revenue and Total Liab go up and down completely randomly.
Correlation Coefficient | 0.04 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from BioAffinity Technologies,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into bioAffinity Technologies, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in bioAffinity Technologies,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.At this time, BioAffinity Technologies,'s Tax Provision is most likely to increase significantly in the upcoming years. The BioAffinity Technologies,'s current Selling General Administrative is estimated to increase to about 7.1 M, while Issuance Of Capital Stock is projected to decrease to 0.00.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.0M | 2.5M | 37.1K | 35.3K | Depreciation And Amortization | 4.8K | 10.2K | 249.6K | 262.1K |
BioAffinity Technologies, fundamental ratios Correlations
Click cells to compare fundamentals
BioAffinity Technologies, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Currently Active Assets on Macroaxis
When determining whether bioAffinity Technologies, is a strong investment it is important to analyze BioAffinity Technologies,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BioAffinity Technologies,'s future performance. For an informed investment choice regarding BioAffinity Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in bioAffinity Technologies,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.744 | Quarterly Revenue Growth 120.474 | Return On Assets (0.70) | Return On Equity (1.52) |
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.